MedPath
HSA Approval

MESTINON TABLET 60 mg

SIN02898P

MESTINON TABLET 60 mg

MESTINON TABLET 60 mg

May 22, 1989

A. MENARINI SINGAPORE PTE. LTD.

A. MENARINI SINGAPORE PTE. LTD.

Regulatory Information

A. MENARINI SINGAPORE PTE. LTD.

A. MENARINI SINGAPORE PTE. LTD.

Therapeutic

Prescription Only

Formulation Information

TABLET, SUGAR COATED

**Indications and dosage** Intestinal atony, atonic constipation: 1 dragée 60mg or 1 – 2 ampoules 1 mg i.m. as required, e.g. at intervals of four hours. Myasthenia gravis: 1 – 3 dragées 60 mg two to four times daily; more in severe cases. If required, single doses of 2 – 5 ampoules s.c. or i.m.

ORAL

Medical Information

The indication(s) is given in the **Dosage** section.

N07AA02

pyridostigmine

Manufacturer Information

A. MENARINI SINGAPORE PTE. LTD.

LABIANA PHARMACEUTICALS S.L.U

Active Ingredients

PYRIDOSTIGMINE BROMIDE

60 mg

Pyridostigmine

Documents

Package Inserts

2013MEN-504-1 Mestinon 60mg 150s Insert (HK,SG) 24May2013.pdf

Approved: July 8, 2013

Download
© Copyright 2025. All Rights Reserved by MedPath